Host: John J. Russell, MD <br>

Guest: Axel Grothey, MD <br>


  <p>In recent years, researchers have been investigating the role of tumor sidedness in metastatic colorectal cancer, and here to walk us through the latest findings and their application to colorectal cancer care is Dr. Axel Grothey.</p>

Host: John J. Russell, MD Guest: Axel Grothey, MD In recent years, researchers have been investigating the role of tumor sidedness in metastatic colorectal cancer, and here to walk us through the latest findings and their application to colorectal cancer care is Dr. Axel Grothey.

Tumor Sidedness in mCRC: Translating the Latest Research Findings into Practice

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location.
To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC).
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 
 Sponsored by

Medicine

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location. To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC). This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location.
To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC).
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
&nbsp;
&nbsp;Sponsored by

Share Tumor Sidedness in mCRC: Translating the Latest Research Findings into Practice

Sign up to save your podcasts

Tumor Sidedness in mCRC: Translating the Latest Research Findings into Practice

Tumor Sidedness in mCRC: Translating the Latest Research Findings into Practice